Lead Sponsor

MedSIR

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•1. Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy
•2. Confirmed diagnosis of HR+/HER2- breast cancer
•3. Post-menopausal status
•4. No prior chemotherapy line in the metastatic setting
•5. Measurable disease defined by RECIST version 1.1, or non-measurable disease
•6. Eastern Cooperative Oncology Group (ECOG) PS 0-1
•7. Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures
•8. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCICTCAE version 4.0 Grade equal or minor than 1

•1. ER or HER2 unknown disease
•2. HER2 positive disease based on local laboratory results
•3. Locally advanced breast cancer candidate for a radical treatment
•4. Prior (neo)adjuvant endocrine treatment with DFI ≤ 12-months from completion of treatment.
•5. Patients with rapidly progressive visceral disease or visceral crisis.
•6. Major surgery within 4 weeks of start of study drug
•7. Patients with an active, bleeding diathesis
•8. Serious concomitant systemic disorder incompatible with the study
•9. Are unable to swallow tablets
•10. Chronic daily treatment with corticosteroids with a dose of ≥ 10mg/day methylprednisolone equivalent
•11. Known active uncontrolled or symptomatic CNS metastases
•12. Known hypersensitivity to letrozole, fulvestrant or any of their excipients, or to any PD-0332991 excipients
•13. QTc \> 480 msec on basal assessments, personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes
•14. Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug

Related studies

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer

NCT06428396 · Metastatic Breast Cancer

NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer

NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, and more

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer